Form 4: Immunovant's Chief Development Officer Sells Shares to Cover Tax Obligations

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 17, 2024, Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 7,825 shares of common stock at a weighted average price of $28.8, with prices ranging from $28.43 to $29.40 per share.
• Additionally, she sold 2,290 shares at a weighted average price of $29.94, with prices ranging from $29.43 to $30.20 per share.
• These sales were mandated by Immunovant to cover tax withholding obligations associated with the vesting of 25,047 restricted stock units on April 12, 2024.
• Following these transactions, Butchko beneficially owns 451,627 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (selling shares to cover taxes) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a company officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the overall market sentiment.

Key Dates